Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 1009-1012

  Kitazawa, Toshiyuki ^a   Tsujimoto, Tatsuhiro ^a   Kawaratani, Hideto ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute liver failure; E5564; Innate immunity; Toll like receptor 4 antagonist; Tumor necrosis factor alpha

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ERITORAN; GALACTOSAMINE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TOLL LIKE RECEPTOR 4; BIOLOGICAL MARKER; LIPID A; LIPOPOLYSACCHARIDE, E COLI O55-B5; TLR4 PROTEIN, RAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; HISTOPATHOLOGY; LIVER FAILURE; MALE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RAT; SALVAGE THERAPY; SURVIVAL RATE; ACUTE LIVER FAILURE; LIVER HISTOLOGY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LIVER FAILURE, ACUTE; METABOLISM; PATHOLOGY; TIME; WISTAR RAT;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; GALACTOSAMINE; INJECTIONS, INTRAVENOUS; LIPID A; LIPOPOLYSACCHARIDES; LIVER; LIVER FAILURE, ACUTE; MALE; RATS; RATS, WISTAR; TIME FACTORS; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951720598     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06145.x     Document Type: Article

References (27)

1. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr., Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002 110 : 191 202.
2. Mullarkey M, Rose JR, Bristol J et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 2003 304 : 1093 1102.
3. Westphal O. Bacterial endotoxins. The second Carl Prausnitz Memorial Lecture. Int. Arch. Allergy Appl. Immunol. 1975 49 : 1 43.
4. Burrell R. Human responses to bacterial endotoxin. Circ. Shock 1994 43 : 137 153.
5. Fiuza C, Suffredini AF. Human models of innate immunity: local and systemic inflammatory responses. J. Endotoxin Res. 2001 7 : 385 388.
6. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006 130 : 1886 1900.
7. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 2003 85 : 85 95.
8. Romics L Jr., Dolganiuc A, Kodys K et al. Selective priming to Toll-like receptor 4 (TLR4), not TLR2, ligands by P. acnes involves up-regulation of MD-2 in mice. Hepatology 2004 40 : 555 564.
9. Kitazawa T, Tsujimoto T, Kawaratani H, Fujimoto M, Fukui H. Expression of Toll-like receptor 4 in various organs in rats with d-galactosamine-induced acute hepatic failure. J. Gastroenterol. Hepatol. 2008 23 : e494 8.
10. Kitazawa T, Tsujimoto T, Kawaratani H, Fukui H. Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with d-galactosamine-induced acute severe liver injury. J. Gastroenterol. Hepatol. 2009 24 : 1089 1094.
11. Alcorn JM, Fierer J, Chojkier M. The acute-phase response protects mice from d-galactosamine sensitization to endotoxin and tumor necrosis factor-alpha. Hepatology 1992 15 : 122 129.
12. Rossignol DP, Hawkins LD, Christ WJ et al. Synthetic endotoxin antagonists. In : Brade H, Opal SM, Vogel SN, Morrison DC, eds. Endotoxin in Health and Disease.
13. Kim HM, Park BS, Kim JI et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007 130 : 906 917.
14. Ondiveeran HK, Fox-Robichaud A. Drug evaluation: E-5564. IDrugs 2004 7 : 582 590.
15. Arvelo MB, Cooper JT, Longo C et al. A20 protects mice from d-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology 2002 35 : 535 543.
16. Nan JX, Park EJ, Nam JB et al. Effect of Acanthopanax koreanum Nakai (Araliaceae) on d-galactosamine and lipopolysaccharide-induced fulminant hepatitis. J. Ethnopharmacol. 2004 92 : 71 7.
17. Liehr H, Grun M, Seelig HP, Seelig R, Reutter W, Heine WD. On the pathogenesis of galactosamine hepatitis. Indications of extrahepatocellular mechanisms responsible for liver cell death. Virchows Archiv. 1978 26 : 331 344.
18. Masubuchi Y, Horie T. Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis. Drug Metab. Dispos. 2004 32 : 437 441.
19. Wang H, Li Y. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and d-galactosamine in mice. Eur. J. Pharmacol. 2006 534 : 194 201.
20. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K. Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol. Res. 2004 29 : 202 206.
21. Leifeld L, Dumoulin FL, Purr I et al. Early up-regulation of chemokine expression in fulminant hepatic failure. J. Pathol. 2003 199 : 335 344.
22. Tracey KJ, Lowry SF, Cerami A. Cachetin/TNF-alpha in septic shock and septic adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1988 138 : 1377 1379.
23. Hirota M, Nozawa F, Okabe A et al. Relationship between plasma cytokine concentration and multiple organ failure in patients with acute pancreatitis. Pancreas 2000 21 : 141 146.
24. Czeslick E, Struppert A, Simm A, Sablotzki A. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes. Inflamm. Res. 2006 55 : 511 515.
25. Lynn M, Wong YN, Wheeler JL et al. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia corrected J. Pharmacol. Exp. Ther. 2004 308 : 175 181.
26. Baumgarten G, Knuefermann P, Schuhmacher G et al. Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia. Shock 2006 25 : 43 9.
27. Savov JD, Brass DM, Lawson BL, McElvania-Tekippe E, Walker JK, Schwartz DA. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am. J. Physiol. 2005 289 : L329 37.